Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39

“Sevion Therapeutics Presents Antibody Discovery Platform at International Conference” Article Was Published Today

 Research, Speculation  Comments Off on “Sevion Therapeutics Presents Antibody Discovery Platform at International Conference” Article Was Published Today
Sep 222015
 

The Hygiology Post ®  has been presenting information about a company formerly called Senesco Technologies which recently merged and rebranded to Sevion Therapeutics that seems to have much potential to help many people. As a matter of disclosure : The author continues to be a current shareholder in the company.

The article published today titled “Sevion Therapeutics Presents Antibody Discovery Platform at International Conference” (https://www.seviontherapeutics.com/sevion-therapeutics-presents-antibody-discovery-platform-at-international-conference/; obtained on 9-22-2015) began the following way:

 “SAN DIEGO, CA – September 22, 2015 – Sevion Therapeutics, Inc. (‘Sevion’ or the ‘Company’)(OTCBB: SVON), a biopharmaceutical company which discovers, develops, and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will give a presentation entitled ‘Antibody Discovery against Multipass Membrane Proteins Directly on the Cell Surface’ at the Discovery On Target Drug Discovery conference in Boston, MA on September 24, 2015, as an invited speaker. Dr. Smider noted, ‘our unique discovery platform, used in our internal discovery efforts as well as large pharma partners, provides a proprietary position in the discovery of monoclonal antibodies against particularly challenging multipass membrane protein targets. With the antibody therapeutics market well validated with now over $50B per year in sales, we believe we are at the forefront in pioneering the next-generation of antibody discovery technologies.’ Dr. Smider added, ‘the first generation of our technology was featured in Nature Biotechnology several years ago, and we are now eager to share the advancements we’ve made in our spatially addressed antibody discovery system in generating leads directly on the cell surface – an important strategy for finding an important strategy for finding drug leads against challenging targets.’ ”

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2015                                    The Hygiology Post ®